Abstracts tagged "connective tissue diseases and interferons"

Abstract Number: 2836 • 2018 ACR/ARHP Annual Meeting
Measurement of Interferon Alpha Expression Using Multiple Methodologies Identifies a Signature in a Subgroup of Connective Tissue Disease Patients with Haematological Abnormalities
John A. Reynolds^1,2, Tracy A. Briggs³, Gillian Rice⁴, Ellen Bruce¹, Sahena Haque⁵, Eoghan McCarthy¹, Ariane L. Herrick^2,6, Hector Chinoy^2,6, Darragh Duffy⁷, Yanick J Crow⁸, Benjamin Parker^2,9 and Ian N. Bruce^1,2, ¹NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ³Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁴Manchester Academic Health Science Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁵Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁶Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, United Kingdom, ⁷Institut Pasteur, Paris, Paris, France, ⁸Institut Imagine, Paris, Paris, France, ⁹NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Interferon alpha (IFNα) is an inflammatory cytokine implicated in the development and persistence of autoimmunity. Although IFNα expression is increased in a subgroup of…
Abstract Number: 679 • 2017 ACR/ARHP Annual Meeting
Distinct Interferon Scores Are Separately Associated with Activity and Long Term Sequelae in SLE
Katherine Dutton¹, Antonios Psarras², Md Yuzaiful Md Yusof², Paul Emery³, Yasser M El-Sherbiny⁴ and Edward M Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom
Background/Purpose: Type I interferon (IFN-I) has a crucial role in the pathogenesis and activity of Systemic Lupus Erythematosis (SLE). IFN-I targeted therapies are currently in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].